Filtered By:
Source: Neurology
Drug: Activase

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 35 results found since Jan 2013.

Impact of Neurologist In-Hospital 24/7 on stroke patients arriving to the Emergency Department activated as a Code Stroke (S8.003)
Conclusions:In-hospital 24/7 coverage for acute stroke treatment reduces door to alteplase treatment times significantly. For each minute reduction in a neurologist at the bedside for CS, a 2 minute and 18 second improvement in door to alteplase treatment time occurs. An associated reduction in mortality is also demonstrated. A limitation of this study includes a smaller number of post-implementation data. These data will need on-going monitoring to ensure enduring impact.Disclosure: Dr. Schneider has nothing to disclose. Dr. Jones has received personal compensation for activities with Genentech as a speaker. Dr. Gosnell h...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Schneider, A., Jones, R., Gosnell, J., Snyder, S., Taylor, R. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Stroke Treatment Source Type: research

Efficency in Emergency Stroke Evaluation is Associated with Patient Volume in Louisianas Level III Hospitals (P6.268)
Conclusions:Higher volume Level III stroke hospitals are more efficient in the components of the stroke code resulting in shorter door-to-needle times for alteplase than lower volume hospitals. However, improvement in efficiency is needed. Global delays in resulting stroke labs may have contributed, but further research is necessary to identify the determinants of prolonged door-to-needle after completion of stroke code components.Disclosure: Dr. Martin-Schild has received personal compensation for activities with Genentech as a speaker. Dr. Hargrove has nothing to disclose. Dr. Chernyshev has nothing to disclose. Dr. Acos...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Martin-Schild, S., Hargrove, P., Chernyshev, O., Acosta, J., DeAlvare, L., Hidalgo, G., El Khoury, R., Navalkele, D. Tags: Cerebrovascular Disease Systems of Care and Health Policy Source Type: research

And why not thrombolysis in the ambulance (at least for some)?
The fear that alteplase may aggravate primary intracerebral hemorrhages has led to the mandatory prerequisite for prealteplase imaging in all acute stroke patients in order to exclude such hemorrhages. Consequently, in a situation in which "time is brain," administration of alteplase is delayed until the patients are transferred to a hospital where such imaging is available, at the cost of additional ischemic damage to the brain parenchyma. Yet, theoretical considerations and empirical data suggest that alteplase's effects on primary intracerebral hemorrhages may not be that detrimental. Moreover, at least some of the pati...
Source: Neurology - July 10, 2016 Category: Neurology Authors: Rosenberg, G., Steiner, I. Tags: CT, All Clinical trials, All Cerebrovascular disease/Stroke, Intracerebral hemorrhage VIEWS & amp;amp; REVIEWS Source Type: research

The New Alteplase (tPA) Package Insert: What Is the Potential Impact? (P2.296)
Conclusions: Our results suggest the new tPA package insert has the potential to increase national tPA treatment rates, decrease U.S. health care costs, and improve functional outcomes in eligible AIS patients. National guidelines need updating to reflect these changes.Disclosure: Dr. Shiue has nothing to disclose. Dr. Albright has nothing to disclose. Dr. Sands has received research support from Biogen. Dr. Sisson has nothing to disclose. Dr. Lyerly has nothing to disclose. Dr. Gropen has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Shiue, H., Albright, K., Sands, K., Sisson, A., Lyerly, M., Gropen, T. Tags: Acute Therapy: IV t-PA Source Type: research

The effect of 24 hour post-intravenous alteplase CT head on management decisions: a single center experience (S47.004)
Conclusion: For 95[percnt] of asymptomatic patients, a 24 hour post-alteplase CT head had no clinical impact. Antithrombotic treatment was delayed by asymptomatic hemorrhage in 2/3 of patients, depriving them of early antiplatelet therapy that reduces the risk of stroke within the first 14 days (Lancet. 349:1569-81). With an estimated 30,000 doses of alteplase given in US, cost of routine CT screening is significant at $6.6 million per year (Jt Comm J Qual Patient Saf. 41:313-22), and there is increased risk of cancer from radiation of 1/10000 (Arch Intern Med. 169:2078-86). Further studies are needed to determine if benef...
Source: Neurology - February 7, 2016 Category: Neurology Authors: Sevilis, T., Morantes Gomez, L., Shah, N., Wang, M., Huang, D., Powers, W. Tags: IV-tPA and Endovascular Therapy Source Type: research

Effect of alteplase on the CT hyperdense artery sign and outcome after ischemic stroke
Conclusions: IV alteplase promotes measurable reduction in HAS regardless of HAS location or extent. Alteplase increased independence at 6 months in patients with and without HAS. Classification of evidence: This study provides Class I evidence that for patients within 6 hours of ischemic stroke with a CT hyperdense artery sign, IV alteplase reduced intra-arterial hyperdense thrombus.
Source: Neurology - January 11, 2016 Category: Neurology Authors: Mair, G., von Kummer, R., Morris, Z., von Heijne, A., Bradey, N., Cala, L., Peeters, A., Farrall, A. J., Adami, A., Potter, G., Cohen, G., Sandercock, P. A. G., Lindley, R. I., Wardlaw, J. M., For the IST-3 Collaborative Group Tags: CT, Clinical trials Randomized controlled (CONSORT agreement), Class I, Infarction ARTICLE Source Type: research

Development and validation of a simplified Stroke-Thrombolytic Predictive Instrument
Conclusion: A simpler model using a 3-item stroke severity score, instead of the 15-item NIH Stroke Scale, has similar prognostic value and may be easier to use in routine care. Future studies are needed to test whether it can improve process and clinical outcomes.
Source: Neurology - September 14, 2015 Category: Neurology Authors: Kent, D. M., Ruthazer, R., Decker, C., Jones, P. G., Saver, J. L., Bluhmki, E., Spertus, J. A. Tags: All Cerebrovascular disease/Stroke ARTICLE Source Type: research

To determine the impact of serum albumin levels on admission with the outcomes in patients receiving IV-t-PA (alteplase) for treatment of acute ischemic stroke. (P5.134)
Conclusion: Among ischemic stroke patients treated with thrombolysis admission hypoalbuminemia was not a predictor of poor outcome. This will need to be validated in larger studies.Disclosure: Dr. Limaye has nothing to disclose. Dr. Lahoti has nothing to disclose. Dr. Hinduja has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Limaye, K., Lahoti, S., Hinduja, A. Tags: Cerebrovascular Disease and Interventional Neurology: Biomarkers and Emerging Science Source Type: research

Embolic stroke with spontaneous recanalization (P3.085)
Conclusions This study infers that thrombolysis remarkably improves clinical outcome in patients with embolic stroke who do not have visible arterial occlusion at presentation. A prospective study to validate these results is being planned.Disclosure: Dr. Lahoti has nothing to disclose. Dr. Gokhale has nothing to disclose. Dr. Caplan has received personal compensation in an editorial capacity for JAMA Neurology. Dr. Michel has received personal compensation for activities with Servier, Sanofi-Aventis Pharmaceuticals, and Boehringer Ingelheim Pharmaceuticals, as a speaker, steering committee member, and/or advisory board me...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Lahoti, S., Gokhale, S., Caplan, L., Michel, P., Samson, Y., Rosso, C., Limaye, K., Hinduja, A., Singhal, A., Ali, S., Kryscio, R., Dedhia, N., Hastak, S., Liebeskind, D., Pettigrew, L. Tags: Cerebrovascular Disease and Interventional Neurology: Hemorrhagic and Ischemic Stroke Source Type: research

Predictors of hematoma volume in the patients treated with intravenous alteplase (P4.297)
CONCLUSIONS: Hematoma volume is related with short and long-term clinical outcomes. Atrial fibrillation and early CT changes are independent predictors of large hematoma volume.Disclosure: Dr. Heo has nothing to disclose. Dr. Lee has nothing to disclose. Dr. Lee has nothing to disclose. Dr. Hwang has nothing to disclose. Dr. Chang has nothing to disclose. Dr. Bu has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Heo, S. H., Lee, J. H., Lee, D., Hwang, K. J., Chang, D.-I., Bu, S. H., Song, J. M., Woo, H.-G. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Ischemic Stroke Treatment Source Type: research

Arterial Reocclusion And Distal Embolization During Endovascular Treatment Using New Generation Stent Retrievers In Acute Ischemic Stroke Patients (P4.299)
CONCLUSIONS: Arterial reocclusion and distal embolization occur in 16[percnt]-18[percnt] of acute ischemic stroke patients undergoing mechanical thrombectomy with new stent retrievers. The rates are no higher than those observed in cohorts treated without stent retrievers.Disclosure: Dr. Herial has nothing to disclose. Dr. Qureshi has nothing to disclose. Dr. Khan has nothing to disclose. Dr. Jahangir has nothing to disclose. Dr. Zeb has nothing to disclose. Dr. Janjua has nothing to disclose. Dr. Suri has nothing to disclose. Dr. Qureshi has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Herial, N., Qureshi, M., Khan, A., Jahangir, N., Zeb, H., Janjua, N., Suri, M., Qureshi, A. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Interventional Treatment for Ischemic Stroke Source Type: research

Urticarial allergic reaction to alteplase: A case report (P6.243)
CONCLUSIONS: Physicians treating acute ischemic stroke with alteplase should be aware of this uncommon but potentially dangerous complication in the spectrum of anaphylactic reactions.Disclosure: Dr. Papolin has nothing to disclose. Dr. Mendes has nothing to disclose. Dr. Lange has nothing to disclose. Dr. Germiniani has nothing to disclose. Dr. Harger has nothing to disclose. Dr. Zetola has nothing to disclose. Dr. Chamma has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Papolin, L., Mendes, D., Lange, M., Germiniani, F., Harger, R., Zetola, V., Chamma, J. Tags: Cerebrovascular Disease and Interventional Neurology: Thrombolysis Complications Source Type: research

"Heparin-Less" Protocol for Endovascular Treatment of Acute Ischemic Stroke (P4.209)
Conclusions: We observed "heparin less" endovascular treatment results in high rates of recanalization with an acceptable rate of post thrombolytic ICH.Disclosure: Dr. Khan has nothing to disclose. Dr. Hassan has nothing to disclose. Dr. Zafar has nothing to disclose. Dr. Malik has nothing to disclose. Dr. Malik has nothing to disclose. Dr. Suri has nothing to disclose. Dr. Qureshi has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Khan, A., Hassan, A., Zafar, T., Malik, A., Adil, M., Suri, M., Qureshi, A. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Stroke Endovascular Source Type: research

Interim Recanalization in Acute Ischemic Stroke Patients Selected for Endovascular Treatment by CT Angiography (P4.210)
Conclusions:A relatively high proportion of patients have interim recanalization between CT angiogram and cerebral angiogram in acute ischemic stroke patients selected for endovascular treatment.Disclosure: Dr. Qureshi has nothing to disclose. Dr. Siddiq has nothing to disclose. Dr. Kainth has nothing to disclose. Dr. Qureshi has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Qureshi, M., Siddiq, F., Kainth, D., Qureshi, A. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Stroke Endovascular Source Type: research

Stroke Outcomes and Usage of IV Alteplase during Pregnancy in the Nationwide Inpatient Sample 2005-2010 (P3.100)
ConclusionsStroke remains a serious complication in pregnancy, and mortality is increasing. Usage of tPA for AIS during pregnancy is minimal, with increased mortality compared to all strokes in pregnancy. Research efforts are needed to improve stroke outcomes during pregnancy.Disclosure: Dr. Ouyang has nothing to disclose. Dr. Knopf has nothing to disclose. Dr. Conners has nothing to disclose. Dr. Cutting has received personal compensation for activities with F1000. Dr. Lee has nothing to disclose. Dr. Smit has nothing to disclose. Dr. Kuklina has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Song, S., Ouyang, B., Knopf, T., Conners, J., Cutting, S., Lee, V., Smit, L., Kuklina, E. Tags: Cerebrovascular Disease and Interventional Neurology: t-PA Source Type: research